SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 242 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.33 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $605,032 | -29.7% | 22,618 | -10.4% | 0.00% | -25.0% |
| Q1 2024 | $860,940 | +7.7% | 25,240 | -8.6% | 0.00% | 0.0% |
| Q4 2023 | $799,323 | +5.0% | 27,620 | -0.0% | 0.00% | 0.0% |
| Q3 2023 | $761,593 | +58349.2% | 27,624 | -15.1% | 0.00% | -60.0% |
| Q4 2022 | $1,303 | -99.9% | 32,528 | -21.5% | 0.01% | -16.7% |
| Q3 2022 | $1,405,000 | +2.1% | 41,453 | -9.8% | 0.01% | +9.1% |
| Q2 2022 | $1,376,000 | +1.0% | 45,938 | -0.1% | 0.01% | +10.0% |
| Q1 2022 | $1,363,000 | -0.5% | 45,973 | -0.3% | 0.01% | 0.0% |
| Q4 2021 | $1,370,000 | -5.5% | 46,128 | -5.2% | 0.01% | +11.1% |
| Q3 2021 | $1,450,000 | +24.3% | 48,656 | -1.8% | 0.01% | +28.6% |
| Q2 2021 | $1,167,000 | -30.5% | 49,568 | -7.3% | 0.01% | -30.0% |
| Q1 2021 | $1,679,000 | +1.3% | 53,466 | -3.4% | 0.01% | -9.1% |
| Q4 2020 | $1,657,000 | +49.8% | 55,356 | +0.5% | 0.01% | +37.5% |
| Q3 2020 | $1,106,000 | -15.1% | 55,060 | -0.3% | 0.01% | -20.0% |
| Q2 2020 | $1,303,000 | +34.6% | 55,225 | +8.2% | 0.01% | +11.1% |
| Q1 2020 | $968,000 | -16.0% | 51,046 | +3.8% | 0.01% | 0.0% |
| Q4 2019 | $1,153,000 | -11.9% | 49,189 | -0.1% | 0.01% | -10.0% |
| Q3 2019 | $1,309,000 | -17.0% | 49,228 | -0.5% | 0.01% | -23.1% |
| Q2 2019 | $1,578,000 | -21.6% | 49,485 | -5.1% | 0.01% | -18.8% |
| Q1 2019 | $2,014,000 | +8.0% | 52,153 | +2.8% | 0.02% | 0.0% |
| Q4 2018 | $1,864,000 | -22.1% | 50,717 | +0.3% | 0.02% | -15.8% |
| Q3 2018 | $2,393,000 | -18.2% | 50,548 | -7.5% | 0.02% | -5.0% |
| Q2 2018 | $2,925,000 | +10.8% | 54,630 | +1.1% | 0.02% | +5.3% |
| Q1 2018 | $2,639,000 | +15.9% | 54,027 | +2.4% | 0.02% | +26.7% |
| Q4 2017 | $2,277,000 | +3.6% | 52,766 | -1.8% | 0.02% | -6.2% |
| Q3 2017 | $2,197,000 | -4.6% | 53,718 | +1.4% | 0.02% | -5.9% |
| Q2 2017 | $2,304,000 | +24.7% | 52,963 | -4.8% | 0.02% | +21.4% |
| Q1 2017 | $1,848,000 | +39.4% | 55,659 | +5.4% | 0.01% | +40.0% |
| Q4 2016 | $1,326,000 | +11.1% | 52,831 | +5.5% | 0.01% | 0.0% |
| Q3 2016 | $1,193,000 | +46.4% | 50,060 | +42.3% | 0.01% | +42.9% |
| Q2 2016 | $815,000 | +43.7% | 35,174 | +1.2% | 0.01% | +40.0% |
| Q1 2016 | $567,000 | +40.7% | 34,761 | +0.9% | 0.01% | +25.0% |
| Q4 2015 | $403,000 | -16.2% | 34,468 | +0.6% | 0.00% | -20.0% |
| Q3 2015 | $481,000 | -51.0% | 34,274 | -40.7% | 0.01% | +25.0% |
| Q2 2015 | $982,000 | – | 57,826 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
| ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
| S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
| Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
| Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
| Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
| Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |